BG105470A - Means and method for the treament of tumours - Google Patents
Means and method for the treament of tumoursInfo
- Publication number
- BG105470A BG105470A BG105470A BG10547001A BG105470A BG 105470 A BG105470 A BG 105470A BG 105470 A BG105470 A BG 105470A BG 10547001 A BG10547001 A BG 10547001A BG 105470 A BG105470 A BG 105470A
- Authority
- BG
- Bulgaria
- Prior art keywords
- treament
- tumours
- acetyldinaline
- capecitabine
- gemcitabine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10180998P | 1998-09-25 | 1998-09-25 | |
| PCT/US1999/015386 WO2000018393A1 (en) | 1998-09-25 | 1999-07-08 | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105470A true BG105470A (en) | 2001-12-29 |
Family
ID=22286531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105470A BG105470A (en) | 1998-09-25 | 2001-04-25 | Means and method for the treament of tumours |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6469058B1 (ko) |
| EP (1) | EP1115391B1 (ko) |
| JP (1) | JP2002525320A (ko) |
| KR (1) | KR20010075348A (ko) |
| CN (1) | CN1319009A (ko) |
| AP (1) | AP2001002109A0 (ko) |
| AT (1) | ATE225655T1 (ko) |
| AU (1) | AU762079B2 (ko) |
| BG (1) | BG105470A (ko) |
| BR (1) | BR9913952A (ko) |
| CA (1) | CA2342981A1 (ko) |
| CZ (1) | CZ2001905A3 (ko) |
| DE (1) | DE69903458T2 (ko) |
| DK (1) | DK1115391T3 (ko) |
| EA (1) | EA200100369A1 (ko) |
| EE (1) | EE200100187A (ko) |
| ES (1) | ES2185378T3 (ko) |
| GE (1) | GEP20043199B (ko) |
| HK (1) | HK1040190A1 (ko) |
| HR (1) | HRP20010225B1 (ko) |
| HU (1) | HUP0103640A3 (ko) |
| ID (1) | ID30046A (ko) |
| IL (1) | IL141951A0 (ko) |
| IS (1) | IS5888A (ko) |
| NO (1) | NO20011493L (ko) |
| NZ (1) | NZ510504A (ko) |
| OA (1) | OA11659A (ko) |
| PL (1) | PL348673A1 (ko) |
| PT (1) | PT1115391E (ko) |
| SK (1) | SK3602001A3 (ko) |
| TR (1) | TR200100859T2 (ko) |
| WO (1) | WO2000018393A1 (ko) |
| YU (1) | YU22401A (ko) |
| ZA (1) | ZA200102233B (ko) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE225655T1 (de) * | 1998-09-25 | 2002-10-15 | Warner Lambert Co | Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| NZ567758A (en) * | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
| AU2003226408B2 (en) * | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| CA2506085A1 (en) * | 2002-11-15 | 2004-06-03 | Ronald Lynn Merriman | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| EP1643971A2 (en) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
| US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
| CN100443081C (zh) * | 2005-04-05 | 2008-12-17 | 吴一心 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
| US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
| WO2007014106A2 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | System and method of delivering radiation therapy to a moving region of interest |
| CA2616272A1 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | System and method of detecting a breathing phase of a patient receiving radiation therapy |
| US7839972B2 (en) | 2005-07-22 | 2010-11-23 | Tomotherapy Incorporated | System and method of evaluating dose delivered by a radiation therapy system |
| US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
| KR20080049716A (ko) * | 2005-07-22 | 2008-06-04 | 토모테라피 인코포레이티드 | 치료 계획의 전달과 관련된 퀄리티 보증 기준을 평가하는방법 및 시스템 |
| CA2616301A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method and system for evaluating delivered dose |
| JP5390855B2 (ja) | 2005-07-23 | 2014-01-15 | トモセラピー・インコーポレーテッド | ガントリおよび治療台の協調した動きを利用した放射線療法の撮像およびデリバリー |
| EP2059254B1 (en) * | 2006-08-31 | 2015-04-08 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| DK2236145T3 (da) * | 2008-01-28 | 2014-08-04 | Nanocarrier Co Ltd | Farmaceutisk sammensætning og kombineret middel |
| FR2937867B1 (fr) * | 2008-11-03 | 2011-03-04 | Biorebus | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. |
| JO3197B1 (ar) | 2009-04-06 | 2018-03-08 | Otsuka Pharma Co Ltd | (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان |
| WO2012003413A1 (en) * | 2010-06-30 | 2012-01-05 | The Broad Institute, Inc. | Novel solid forms of tacedinaline |
| US8691875B2 (en) | 2011-07-01 | 2014-04-08 | Broad Institute, Inc. | Solid forms of tacedinaline |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| EP2711008A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer |
| EP2711007A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer |
| EP2711009A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer |
| EP2962309B1 (en) | 2013-02-26 | 2022-02-16 | Accuray, Inc. | Electromagnetically actuated multi-leaf collimator |
| US10189797B2 (en) * | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
| US11987579B2 (en) | 2018-07-30 | 2024-05-21 | Duke University | Niclosamide analogues and therapeutic use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5562925A (en) * | 1970-04-20 | 1996-10-08 | Research Corporation Tech. Inc. | Anti-tumor method |
| NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
| AU671491B2 (en) * | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| AU6878198A (en) | 1997-04-24 | 1998-11-13 | Warner-Lambert Company | Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| ATE225655T1 (de) * | 1998-09-25 | 2002-10-15 | Warner Lambert Co | Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin |
-
1999
- 1999-07-08 AT AT99935442T patent/ATE225655T1/de not_active IP Right Cessation
- 1999-07-08 AU AU50921/99A patent/AU762079B2/en not_active Ceased
- 1999-07-08 ID IDW20010901A patent/ID30046A/id unknown
- 1999-07-08 GE GEAP19995872A patent/GEP20043199B/en unknown
- 1999-07-08 PL PL99348673A patent/PL348673A1/xx not_active Application Discontinuation
- 1999-07-08 OA OA1200100078A patent/OA11659A/en unknown
- 1999-07-08 CZ CZ2001905A patent/CZ2001905A3/cs unknown
- 1999-07-08 HU HU0103640A patent/HUP0103640A3/hu unknown
- 1999-07-08 PT PT99935442T patent/PT1115391E/pt unknown
- 1999-07-08 EA EA200100369A patent/EA200100369A1/ru unknown
- 1999-07-08 ES ES99935442T patent/ES2185378T3/es not_active Expired - Lifetime
- 1999-07-08 AP APAP/P/2001/002109A patent/AP2001002109A0/en unknown
- 1999-07-08 US US09/744,130 patent/US6469058B1/en not_active Expired - Fee Related
- 1999-07-08 BR BR9913952-9A patent/BR9913952A/pt not_active IP Right Cessation
- 1999-07-08 YU YU22401A patent/YU22401A/sh unknown
- 1999-07-08 IL IL14195199A patent/IL141951A0/xx unknown
- 1999-07-08 CN CN99811320A patent/CN1319009A/zh active Pending
- 1999-07-08 CA CA002342981A patent/CA2342981A1/en not_active Abandoned
- 1999-07-08 TR TR2001/00859T patent/TR200100859T2/xx unknown
- 1999-07-08 SK SK360-2001A patent/SK3602001A3/sk unknown
- 1999-07-08 WO PCT/US1999/015386 patent/WO2000018393A1/en not_active Application Discontinuation
- 1999-07-08 EE EEP200100187A patent/EE200100187A/xx unknown
- 1999-07-08 EP EP99935442A patent/EP1115391B1/en not_active Expired - Lifetime
- 1999-07-08 DK DK99935442T patent/DK1115391T3/da active
- 1999-07-08 KR KR1020017003794A patent/KR20010075348A/ko not_active Application Discontinuation
- 1999-07-08 DE DE69903458T patent/DE69903458T2/de not_active Expired - Fee Related
- 1999-07-08 JP JP2000571912A patent/JP2002525320A/ja active Pending
- 1999-07-08 NZ NZ510504A patent/NZ510504A/en unknown
-
2001
- 2001-03-14 IS IS5888A patent/IS5888A/is unknown
- 2001-03-16 ZA ZA200102233A patent/ZA200102233B/en unknown
- 2001-03-23 NO NO20011493A patent/NO20011493L/no not_active Application Discontinuation
- 2001-03-23 HR HR20010225A patent/HRP20010225B1/xx not_active Application Discontinuation
- 2001-04-25 BG BG105470A patent/BG105470A/xx unknown
-
2002
- 2002-03-01 HK HK02101589.3A patent/HK1040190A1/zh unknown
- 2002-10-08 US US10/184,309 patent/US20030170300A1/en not_active Abandoned
- 2002-10-09 US US10/185,221 patent/US20030086965A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105470A (en) | Means and method for the treament of tumours | |
| IL100942A0 (en) | 2,4-diaminoquinazoline derivatives for enhancing antitumor activity | |
| MXPA01004648A (es) | Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20. | |
| AU2592600A (en) | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
| HU9301314D0 (en) | Quinazoline derivatves for improving anto-tumouric activity | |
| BG102999A (en) | New 2,3-diasubstituted-4-(3h)-quinazolinons | |
| SG144712A1 (en) | Nordihydroguaiartic derivaties for use in treatment of tumors | |
| NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
| IL134445A0 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
| MY137303A (en) | Methods for treating proliferative diseases | |
| NZ512210A (en) | Camptothecin analogs useful for treating cancer and leukemia | |
| HU9503625D0 (en) | Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema | |
| DE3685484D1 (ko) | ||
| HU9701060D0 (en) | Pharmaceutical composition for treating cognitive disturbs | |
| IL131478A0 (en) | Methods for treatment of scar tissue | |
| AU3600199A (en) | A pharmaceutical composition containing ezrin mutated on tyrosine 353 | |
| EP0938900A4 (en) | MEANS OF PREVENTION OR HEALING OF STOMATITIS | |
| IL145149A0 (en) | Radioactive cisplatin in the treatment of cancer | |
| ZA200101188B (en) | DNAzymes and methods for treating restenosis. | |
| EP1083914A4 (en) | TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS | |
| IL133141A0 (en) | Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps | |
| ATE179987T1 (de) | Vitamin b 12-haltige sanddornkonzentrate oder - extrakte | |
| CA2259997A1 (en) | Remedies and preventives for stomatitis | |
| MXPA05002477A (es) | Asialo-interferones y el tratamiento de cancer de higado. |